CY1122578T1 - Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα - Google Patents
Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμαInfo
- Publication number
- CY1122578T1 CY1122578T1 CY20191101334T CY191101334T CY1122578T1 CY 1122578 T1 CY1122578 T1 CY 1122578T1 CY 20191101334 T CY20191101334 T CY 20191101334T CY 191101334 T CY191101334 T CY 191101334T CY 1122578 T1 CY1122578 T1 CY 1122578T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical preparation
- antibody
- specifically
- protein
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ένα φαρμακευτικό σκεύασμα, συγκεκριμένα με ένα φαρμακευτικό σκεύασμα το οποίο περιλαμβάνει μια πρωτεΐνη, πιο συγκεκριμένα ένα αντίσωμα ως δραστικό συστατικό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15154301 | 2015-02-09 | ||
PCT/EP2016/052494 WO2016128318A1 (en) | 2015-02-09 | 2016-02-05 | Pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122578T1 true CY1122578T1 (el) | 2021-01-27 |
Family
ID=52477586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191101334T CY1122578T1 (el) | 2015-02-09 | 2019-12-18 | Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα |
Country Status (23)
Country | Link |
---|---|
US (1) | US10039826B2 (el) |
EP (1) | EP3256154B1 (el) |
JP (1) | JP6784683B2 (el) |
CN (1) | CN107249571B (el) |
AU (1) | AU2016218074B2 (el) |
BR (1) | BR112017014414B1 (el) |
CA (1) | CA2973423C (el) |
CO (1) | CO2017007316A2 (el) |
CY (1) | CY1122578T1 (el) |
DK (1) | DK3256154T5 (el) |
EA (1) | EA035719B1 (el) |
ES (1) | ES2763309T3 (el) |
HR (1) | HRP20192222T1 (el) |
HU (1) | HUE047860T2 (el) |
IL (1) | IL253177B (el) |
LT (1) | LT3256154T (el) |
MX (1) | MX2017009827A (el) |
MY (1) | MY183068A (el) |
PL (1) | PL3256154T3 (el) |
PT (1) | PT3256154T (el) |
SG (1) | SG11201705484WA (el) |
SI (1) | SI3256154T1 (el) |
WO (1) | WO2016128318A1 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111278459A (zh) * | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
MX2021002935A (es) * | 2018-09-13 | 2021-06-15 | Hoffmann La Roche | Formulacion de anticuerpos contra csf-1r. |
UA128098C2 (uk) | 2019-02-18 | 2024-04-03 | Елі Ліллі Енд Компані | Водна фармацевтична композиція антитіла проти il-17a |
TW202332471A (zh) | 2021-12-01 | 2023-08-16 | 比利時商Ucb生物製藥公司 | 調配物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101512007A (zh) * | 2005-10-13 | 2009-08-19 | 人体基因组科学有限公司 | 用于治疗自身抗体阳性疾病患者的方法和组合物 |
KR20140077946A (ko) * | 2005-10-13 | 2014-06-24 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
RU2626512C2 (ru) * | 2010-03-01 | 2017-07-28 | Цитодин, Инк. | Концентрированные белковые фармацевтические составы и их применение |
EA036336B1 (ru) * | 2010-05-04 | 2020-10-28 | Файв Прайм Терапьютикс, Инк. | Связывающие csf1r антитела |
JP6242804B2 (ja) * | 2011-12-15 | 2017-12-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトcsf−1rに対する抗体及びその使用 |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
-
2016
- 2016-02-05 SI SI201630566T patent/SI3256154T1/sl unknown
- 2016-02-05 ES ES16703297T patent/ES2763309T3/es active Active
- 2016-02-05 EP EP16703297.8A patent/EP3256154B1/en active Active
- 2016-02-05 PT PT167032978T patent/PT3256154T/pt unknown
- 2016-02-05 WO PCT/EP2016/052494 patent/WO2016128318A1/en active Application Filing
- 2016-02-05 PL PL16703297T patent/PL3256154T3/pl unknown
- 2016-02-05 LT LTEP16703297.8T patent/LT3256154T/lt unknown
- 2016-02-05 CN CN201680009192.XA patent/CN107249571B/zh active Active
- 2016-02-05 JP JP2017541820A patent/JP6784683B2/ja active Active
- 2016-02-05 DK DK16703297.8T patent/DK3256154T5/da active
- 2016-02-05 MY MYPI2017702619A patent/MY183068A/en unknown
- 2016-02-05 SG SG11201705484WA patent/SG11201705484WA/en unknown
- 2016-02-05 CA CA2973423A patent/CA2973423C/en active Active
- 2016-02-05 HU HUE16703297A patent/HUE047860T2/hu unknown
- 2016-02-05 MX MX2017009827A patent/MX2017009827A/es active IP Right Grant
- 2016-02-05 EA EA201791716A patent/EA035719B1/ru not_active IP Right Cessation
- 2016-02-05 BR BR112017014414-0A patent/BR112017014414B1/pt active IP Right Grant
- 2016-02-05 AU AU2016218074A patent/AU2016218074B2/en active Active
- 2016-02-05 US US15/549,528 patent/US10039826B2/en active Active
-
2017
- 2017-06-26 IL IL253177A patent/IL253177B/en unknown
- 2017-07-24 CO CONC2017/0007316A patent/CO2017007316A2/es unknown
-
2019
- 2019-12-11 HR HRP20192222TT patent/HRP20192222T1/hr unknown
- 2019-12-18 CY CY20191101334T patent/CY1122578T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US10039826B2 (en) | 2018-08-07 |
EP3256154B1 (en) | 2019-10-02 |
CA2973423A1 (en) | 2016-08-18 |
DK3256154T5 (da) | 2020-01-27 |
DK3256154T3 (da) | 2020-01-02 |
LT3256154T (lt) | 2020-01-10 |
US20180028652A1 (en) | 2018-02-01 |
HUE047860T2 (hu) | 2020-05-28 |
AU2016218074A1 (en) | 2017-07-20 |
BR112017014414B1 (pt) | 2024-01-23 |
JP6784683B2 (ja) | 2020-11-11 |
PT3256154T (pt) | 2020-01-09 |
CA2973423C (en) | 2023-09-05 |
EA201791716A1 (ru) | 2017-12-29 |
CN107249571B (zh) | 2021-03-12 |
MY183068A (en) | 2021-02-10 |
KR20170115090A (ko) | 2017-10-16 |
EA035719B1 (ru) | 2020-07-30 |
SG11201705484WA (en) | 2017-08-30 |
MX2017009827A (es) | 2017-11-02 |
EP3256154A1 (en) | 2017-12-20 |
BR112017014414A2 (pt) | 2018-05-15 |
SI3256154T1 (sl) | 2020-02-28 |
WO2016128318A1 (en) | 2016-08-18 |
AU2016218074B2 (en) | 2020-01-30 |
CN107249571A (zh) | 2017-10-13 |
IL253177B (en) | 2021-12-01 |
JP2018505894A (ja) | 2018-03-01 |
IL253177A0 (en) | 2017-08-31 |
CO2017007316A2 (es) | 2017-10-20 |
PL3256154T3 (pl) | 2021-07-19 |
HRP20192222T1 (hr) | 2020-02-21 |
ES2763309T3 (es) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124004T1 (el) | Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους | |
EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
DK3577110T3 (da) | 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer | |
EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
DK3283521T3 (da) | Lægemiddelkonjugater, der omfatter antistoffer mod claudin 18.2 | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
DK3408295T3 (da) | Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner | |
EA201991715A1 (ru) | Композиции, содержащие антитело к pdl1 | |
CY1122578T1 (el) | Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα | |
CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
BR112018075644A2 (pt) | anticorpos anti-cd98 e conjugados de anticorpo e fármaco | |
EA201790184A1 (ru) | Пестицидные композиции | |
CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
TR201910057T4 (tr) | Kauçuk bi̇leşi̇mleri̇ | |
EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
EA201792000A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
TR201901228T4 (tr) | Vortioksetin piroglutamat. | |
EA202090402A1 (ru) | Фармацевтическая композиция, содержащая пальбоциклиб | |
CO2017010143A2 (es) | Procesos para preparar fluorocetólidos | |
CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
EA201691203A1 (ru) | Твёрдые формы тенофовира | |
EA201790482A1 (ru) | Модифицированные полипептиды vip3 | |
EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола |